Melanoma

Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson, Adil Daud, Raza A. Dilawari, Dominick DiMaio, Valerie Guild, Allan C. Halpern, F. Stephen Hodi, Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. Ross & 5 others Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, Marshall M. Urist

Research output: Contribution to journalArticle

Abstract

These guidelines represent an effort to distill and simplify an enormous body of knowledge and experience into fairly simple management algorithms. In general, treatment recommendations for primary tumors are based on better data than those for treating recurrent disease. Few, if any, firm recommendations can be made about more controversial issues for patients with melanoma, such as the extent of workup or intensity of follow-up. These guidelines are intended as a point of departure, recognizing that all clinical decisions about individual patient management must be tempered by clinician judgment and other factors, such as local resources and expertise and the individual patient's needs, wishes, and expectations. Furthermore, these guidelines undergo annual revision and are continually updated as new data become available.

Original languageEnglish (US)
Pages (from-to)366-400
Number of pages35
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume10
Issue number3
StatePublished - Mar 1 2012

Fingerprint

Melanoma
Guidelines
Neoplasms
Therapeutics

Keywords

  • Adjuvant therapy
  • Biopsy
  • Chemotherapy
  • Interferon
  • Lymph node dissection
  • Margin
  • Melanoma
  • Metastases
  • NCCN clinical practice guidelines
  • NCCN guidelines
  • Pathology
  • Radiation therapy
  • Sentinel lymph node
  • Skin cancer
  • Surgical excision

ASJC Scopus subject areas

  • Oncology

Cite this

Coit, D. G., Andtbacka, R., Anker, C. J., Bichakjian, C. K., Carson, W. E., Daud, A., ... Urist, M. M. (2012). Melanoma. JNCCN Journal of the National Comprehensive Cancer Network, 10(3), 366-400.

Melanoma. / Coit, Daniel G.; Andtbacka, Robert; Anker, Christopher J.; Bichakjian, Christopher K.; Carson, William E.; Daud, Adil; Dilawari, Raza A.; DiMaio, Dominick; Guild, Valerie; Halpern, Allan C.; Hodi, F. Stephen; Kelley, Mark C.; Khushalani, Nikhil I.; Kudchadkar, Ragini R.; Lange, Julie R; Lind, Anne; Martini, Mary C.; Olszanski, Anthony J.; Pruitt, Scott K.; Ross, Merrick I.; Swetter, Susan M.; Tanabe, Kenneth K.; Thompson, John A.; Trisal, Vijay; Urist, Marshall M.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 10, No. 3, 01.03.2012, p. 366-400.

Research output: Contribution to journalArticle

Coit, DG, Andtbacka, R, Anker, CJ, Bichakjian, CK, Carson, WE, Daud, A, Dilawari, RA, DiMaio, D, Guild, V, Halpern, AC, Hodi, FS, Kelley, MC, Khushalani, NI, Kudchadkar, RR, Lange, JR, Lind, A, Martini, MC, Olszanski, AJ, Pruitt, SK, Ross, MI, Swetter, SM, Tanabe, KK, Thompson, JA, Trisal, V & Urist, MM 2012, 'Melanoma', JNCCN Journal of the National Comprehensive Cancer Network, vol. 10, no. 3, pp. 366-400.
Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A et al. Melanoma. JNCCN Journal of the National Comprehensive Cancer Network. 2012 Mar 1;10(3):366-400.
Coit, Daniel G. ; Andtbacka, Robert ; Anker, Christopher J. ; Bichakjian, Christopher K. ; Carson, William E. ; Daud, Adil ; Dilawari, Raza A. ; DiMaio, Dominick ; Guild, Valerie ; Halpern, Allan C. ; Hodi, F. Stephen ; Kelley, Mark C. ; Khushalani, Nikhil I. ; Kudchadkar, Ragini R. ; Lange, Julie R ; Lind, Anne ; Martini, Mary C. ; Olszanski, Anthony J. ; Pruitt, Scott K. ; Ross, Merrick I. ; Swetter, Susan M. ; Tanabe, Kenneth K. ; Thompson, John A. ; Trisal, Vijay ; Urist, Marshall M. / Melanoma. In: JNCCN Journal of the National Comprehensive Cancer Network. 2012 ; Vol. 10, No. 3. pp. 366-400.
@article{a2e936deba9947a9a67df4068618177f,
title = "Melanoma",
abstract = "These guidelines represent an effort to distill and simplify an enormous body of knowledge and experience into fairly simple management algorithms. In general, treatment recommendations for primary tumors are based on better data than those for treating recurrent disease. Few, if any, firm recommendations can be made about more controversial issues for patients with melanoma, such as the extent of workup or intensity of follow-up. These guidelines are intended as a point of departure, recognizing that all clinical decisions about individual patient management must be tempered by clinician judgment and other factors, such as local resources and expertise and the individual patient's needs, wishes, and expectations. Furthermore, these guidelines undergo annual revision and are continually updated as new data become available.",
keywords = "Adjuvant therapy, Biopsy, Chemotherapy, Interferon, Lymph node dissection, Margin, Melanoma, Metastases, NCCN clinical practice guidelines, NCCN guidelines, Pathology, Radiation therapy, Sentinel lymph node, Skin cancer, Surgical excision",
author = "Coit, {Daniel G.} and Robert Andtbacka and Anker, {Christopher J.} and Bichakjian, {Christopher K.} and Carson, {William E.} and Adil Daud and Dilawari, {Raza A.} and Dominick DiMaio and Valerie Guild and Halpern, {Allan C.} and Hodi, {F. Stephen} and Kelley, {Mark C.} and Khushalani, {Nikhil I.} and Kudchadkar, {Ragini R.} and Lange, {Julie R} and Anne Lind and Martini, {Mary C.} and Olszanski, {Anthony J.} and Pruitt, {Scott K.} and Ross, {Merrick I.} and Swetter, {Susan M.} and Tanabe, {Kenneth K.} and Thompson, {John A.} and Vijay Trisal and Urist, {Marshall M.}",
year = "2012",
month = "3",
day = "1",
language = "English (US)",
volume = "10",
pages = "366--400",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "3",

}

TY - JOUR

T1 - Melanoma

AU - Coit, Daniel G.

AU - Andtbacka, Robert

AU - Anker, Christopher J.

AU - Bichakjian, Christopher K.

AU - Carson, William E.

AU - Daud, Adil

AU - Dilawari, Raza A.

AU - DiMaio, Dominick

AU - Guild, Valerie

AU - Halpern, Allan C.

AU - Hodi, F. Stephen

AU - Kelley, Mark C.

AU - Khushalani, Nikhil I.

AU - Kudchadkar, Ragini R.

AU - Lange, Julie R

AU - Lind, Anne

AU - Martini, Mary C.

AU - Olszanski, Anthony J.

AU - Pruitt, Scott K.

AU - Ross, Merrick I.

AU - Swetter, Susan M.

AU - Tanabe, Kenneth K.

AU - Thompson, John A.

AU - Trisal, Vijay

AU - Urist, Marshall M.

PY - 2012/3/1

Y1 - 2012/3/1

N2 - These guidelines represent an effort to distill and simplify an enormous body of knowledge and experience into fairly simple management algorithms. In general, treatment recommendations for primary tumors are based on better data than those for treating recurrent disease. Few, if any, firm recommendations can be made about more controversial issues for patients with melanoma, such as the extent of workup or intensity of follow-up. These guidelines are intended as a point of departure, recognizing that all clinical decisions about individual patient management must be tempered by clinician judgment and other factors, such as local resources and expertise and the individual patient's needs, wishes, and expectations. Furthermore, these guidelines undergo annual revision and are continually updated as new data become available.

AB - These guidelines represent an effort to distill and simplify an enormous body of knowledge and experience into fairly simple management algorithms. In general, treatment recommendations for primary tumors are based on better data than those for treating recurrent disease. Few, if any, firm recommendations can be made about more controversial issues for patients with melanoma, such as the extent of workup or intensity of follow-up. These guidelines are intended as a point of departure, recognizing that all clinical decisions about individual patient management must be tempered by clinician judgment and other factors, such as local resources and expertise and the individual patient's needs, wishes, and expectations. Furthermore, these guidelines undergo annual revision and are continually updated as new data become available.

KW - Adjuvant therapy

KW - Biopsy

KW - Chemotherapy

KW - Interferon

KW - Lymph node dissection

KW - Margin

KW - Melanoma

KW - Metastases

KW - NCCN clinical practice guidelines

KW - NCCN guidelines

KW - Pathology

KW - Radiation therapy

KW - Sentinel lymph node

KW - Skin cancer

KW - Surgical excision

UR - http://www.scopus.com/inward/record.url?scp=84863393453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863393453&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 366

EP - 400

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 3

ER -